

Pagina 6 | Rubriek Interacties - Neuropathische pijn (Han Siem)

- van Doorn, P. *Richtlijn 'Neuropathie'*. Ned Tijdschr Geneesk. 2007;151:1566-73.
- Geneesmiddeleninduceerde perifere neuropathie*. Ge Bun r 4 (2014) pagina 39-45. Geraadpleegd op 2 december via <https://www.ge-bu.nl/artikel/geneesmiddeleninduceerde-perifere-neuropathie>
- Keppel Hesselink JM. *New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide*. Open Pain J. 2012;5:12-23.
- Keppel Hesselink JM, de Boer T, Witkamp R. *Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold*. Int J Inflammation. 2013.
- Desio P. *Pregabalin and Palmitoylethanolamide in the treatment of neuropathic pain*. Pathos 2010117:9-14.
- The Natural Standard. *PEA productmonografie*.
- Salehi B et al. *Insights on the use of alpha-lipoic acid for therapeutic purposes*. Biomolecules. 2019;9(8):356.
- Uberti F et al. *A combination of alpha-lipoic acid (ALA) and palmitoylethanolamide (PEA) blocks endotoxin-induced oxidative stress and cytokine storm: a possible intervention for COVID-19*. J Diet Suppl. 2021 Aug 18:1-23.
- Labriola D, Livingston R. *Possible interactions between dietary antioxidants and chemotherapy*. Oncology 1999;13:1003-8.
- Prasad KN. *Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy*. J Nutr 2004;134:3182S-3S.
- Conklin KA. *Cancer chemotherapy and antioxidants*. J Nutr 2004;134:3201S-3204S.
- Karkabounas S, Papadopoulos N, Anastasiadou C, et al. *Effects of α -lipoic Acid, carnosine, and thiamine supplementation in obese patients with type 2 diabetes mellitus: A randomized, double-blind study*. J Med Food. 2018;21(12):1197-1203.
- Derosa G, D'Angelo A, Preti P, Maffioli P. *Safety and efficacy of alpha lipoic acid during 4 years of observation: A retrospective, clinical trial in healthy subjects in primary prevention*. Drug Des Devel Ther. 2020;14:5367-5374.
- Ebada MA, Fayed N, Fayed L, et al. *Efficacy of alpha-lipoic acid in the management of diabetes mellitus: A systematic review and meta-analysis*. Iran J Pharm Res. 2019;18(4):2144-2156.
- Segermann J, Hotze A, Ulrich H, Rao GS. *Effect of alpha-lipoic acid on the peripheral conversion of tyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels*. Arzneimittelforschung 1991;41:1294-8.
- Fogacci F et al. *Safety evaluation of alpha-lipoic acid supplementation: a systematic review and meta-analysis of randomized placebo-controlled clinical studies*. Antioxidants (Basel). 2020;9(10):1011.
- della Rocca G, Gamba D. *Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?* Animals 2021, 11(4), 952.

Pagina 10 | Pathofysiologie van long covid (Marloes van Heijningen-Waanders)

- Buonsenso D, Di Gennaro L, De Rose C, Morello R, D'Ilario F, Zampino G, et al. *Long-term outcomes of pediatric infections: from traditional infectious diseases to long covid*. Future Microbiol. 2022 May;17:551-571.
- Castanares-Zapatero D, Chalón P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. *Pathophysiology and mechanism of long covid: a comprehensive review*. Ann Med. 2022 Dec;54(1):1473-1487.
- Bonaventura A, Vecchiè A, Dagna L, Martinod K, Dixon DL, Van Tassel BW, et al. *Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19*. Nat Rev Immunol. 2021 May;21(5):319-329.
- Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. *Persistent clotting protein pathology in Long covid/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplastin*. Cardiovasc Diabetol. 2021 Aug 23;20(1):172.
- Scurati R, Papini N, Giussani P, Alberti G, Tringali C. *The Challenge of Long covid-19 Management: From Disease Molecular Hallmarks to the Proposal of Exercise as Therapy*. Int J Mol Sci. 2022 Oct 14;23(20):12311.
- Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. *Diverse functional autoantibodies in patients with COVID-19*. Nature. 2021 Jul;595(7866):283-288.
- Silva CC, Bichara CNC, Carneiro FRO, Palacios VR da CM, Berg AVSV den, Quaresma JAS, et al. *Muscle dysfunction in the long coronavirus disease 2019 syndrome: Pathogenesis and clinical approach*. Rev Med Virol. 2022 Nov;32(6):e2355.
- Silverio R, Gonçalves DC, Andrade MF, Seelaender M. *Coronavirus Disease 2019 (COVID-19) and Nutritional Status: The Missing Link?* Adv Nutr. 2021 Jun 1;12(3):682-692.
- Singh S, Kola P, Kaur D, Singla G, Mishra V, Panesar PS, et al. *Therapeutic Potential of Nutraceuticals and Dietary Supplements in the Prevention of Viral Diseases: A Review*. Front Nutr. 2021;8:679312.
- Barrea L, Grant WB, Frias-Toral E, Vetrani C, Verde L, de Alteriis G, et al. *Dietary Recommendations for Post-COVID-19 Syndrome*. Nutrients. 2022 Mar 20;14(6):1305.
- Calder PC, Carr AC, Gombart AF, Eggertsdorfer M. *Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections*. Nutrients. 2020 Apr 23;12(4):E1181.
- Wang J, Liu S, Li G, Xiao J. *Exercise Regulates the Immune System*. Adv Exp Med Biol. 2020;1228:395-408.

Pagina 16 | Voedingstoffen bij longcovidklachten (Ilse van Bladel en Jeroen de Haas)

- Tosato, M. et al. *Nutraceuticals and dietary supplements for older adults with long COVID-19*. Clin Geriatr Med 2022; 38:565-591.
- Naureen, Z. et al. *Proposal of a food supplement for the management of post-COVID syndrome*. European review for Medical and Pharmacological Sciences 2021; 25(1 Suppl): 67-73.
- Yang C.P. et al. *Long COVID and long chain fatty acids (LCFAs): Psychoneuro-immunity implication of omega-3 LCFAs in delayed consequences of COVID-19*. Brain Behav Immun. 2022; 103:19-27.
- Majeed, M. et al. *Can Selenium Reduce the Susceptibility and Severity of SARS-CoV-2?—A Comprehensive Review*. International Journal of Molecular Sciences. 2022; 23(9): 4809.
- Sumbalova Z. et al. *Platelet mitochondrial function and endogenous coenzyme Q10 levels are reduced in patients after COVID-19*. Bratisl Lek Listy. 2022;123(1):9-15.
- Janssen R., et al. *Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019*. Br J Nutr. 2021; 126(2):191-198.
- Iwegbulem O, et al. *The role of taurine derivatives in the putative therapy of COVID-19-induced inflammation*. Ir J Med Sci. 2022; Feb;191(1):485-486.
- Izzo R, et al. *Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey*. Pharmacol Res. 2022; 183:106360.
- Karosanidze, I. et al. *Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial*. Pharmaceuticals (Basel). 2022; 15(3): 345.
- Morello R, et al. *Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review*. Children (Basel). 2022; 9(10):1446.

Pagina 22 | Neuro-covid en de rol van micronutriënten (Margot Lodewijk)

- Adlimoghaddam, A. et al. *Neurocovid, Neuroinflammation, and Nuclear Factor-kB: The Role for Micronutrients*. Journal Of Integrative And Complementary Medicine Volume 28, Number 12, 2022.
- Russchen F. *Neuro-Covid, schade en protectie*. Ortho Fytho, juni 2021.
- Davies DA, Adlimoghaddam A, Albensi BC. *The effect of COVID-19 on NF kappa B and neurological manifestations of disease*. Mol Neurobiol 2021;58(8):4178-4187.
- Chou SH, Beghi E, Helbok, et al. *Global incidence of neurological manifestations among patients hospitalized with COVID-19—A report for the GCS-NeuroCOVID consortium and the ENERGY consortium*. JAMA Netw Open 2021; 4(5):e2112131.
- Monografie van Natura Foundation: <https://www.naturafoundation.nl/kenniscentrum/monografie/9/curcuma-longa>
- Meinhardt J, Radke J, Dittmayer C, et al. *Olfactory trans mucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19*. Nat Neurosci 2021;24(2):168-175.
- Chen R, Wang K, Yu J, et al. *The spatial and cell type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains*. Front Neurol 2020;11:573095.
- DeDiego ML, Nieto-Torres JL, Regla-Nava JA, et al. *Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival*. J Virol 2014;88(2):913-924; doi: 10.1128/JVI.02576-13.
- Cimmino G, Morello A, Conte S, et al. *Vitamin D inhibits tissue factor and Cx43 expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF-kB pathway*. Eur J Pharmacol 2020;885:173422; doi: 10.1016/j.ejphar.2020.173422.
- Menendez SG, Gimenez VMM, Holick MF, et al. 2022. *COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent*. Life Sci 2022;297:120464; doi: 10.1016/j.lfs.2022.120464.
- Weyh C, Kruger K, Peeling P, et al. *The role of minerals in the optimal functioning of the immune system*. Nutrients 2022;14:644.
- Herbein G, Varin A, Fulop T. *NF-kB, AP-1, Zinc- deficiency and aging*. Biogerontology 2006;7(5):409-419.
- Khatiawada S, Subedi A. *A mechanistic link between selenium and coronavirus disease 2019 (COVID-19)*. Curr Nutr Rep 2021;10(2):125-136.
- Al Sulaiman K, Aljuhani O, Al Dossari M, et al. *Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: A two-center propensity score matched study*. Crit Care 2021;25:223.
- Mahdavi S, Dehghani R, Jeddi F, et al. *Thiamine reduced metabolic syndrome symptoms in rats via down-regulation of hepatic nuclear factor-kb and induction activity of glyoxalase-I*. Iran J Basic Med Sci 2021;24(3): 293-299.
- Marrs C, Lonsdale D. *Hiding in plain sight: Modern thiamine deficiency*. Cells 2021;10:2595.
- Ravula AR, Teegala SB, Kalakotla S, et al. *Fisetin, potential flavonoid with multifarious targets for treating neurological disorders: An updated review*. Eur J Pharma-col 2021;910:174492.
- Currais A, Prior M, Dargusch R, et al. *Modulation of p25 and inflammatory pathways by Fisetin maintains cognitive function in Alzheimer's disease transgenic mice*. Aging Cell 2014;13(2):379-390.
- Monografie van Natura Foundation: <https://www.naturafoundation.nl/kenniscentrum/monografie/208/flavonoiden>
- Castanares-Zapatero, D., Chalón, P., Kohn, L., Dauvrin, M., Detollenaere, J., Maertens de Noordhout, C., Primus-de Jong, C., Cleemput, I., & Van den Heede, K. (2022). *Pathophysiology and mechanism of long COVID: a comprehensive review*. Annals of medicine, 54(1), 1473-1487.

Pagina 29 | (Gefermenteerde) shiitake (Geert Verhelst)

- Roszczyk A, Turlo J, Zagodzón R, Kaleta B. *Immunomodulatory Properties of Polysaccharides from Lentinula edodes*. Int J Mol Sci. 2022;23(16):8980. Published 2022 Aug 11.
- Dai X, Stanilka JM, Rowe CA, Esteves EA, Nieves C Jr, Spaiser SJ, Christman MC, Langkamp-Henken B, Percival SS. *Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults*. J Am Coll Nutr. 2015;34(6):478-87. Epub 2015 Apr 11. PMID: 25866155.
- Tani M., Tanimura H., Yamaue H., Tsunoda T., Iwahashi M., Noguchi K., Tamai M., Hotta T., Mizobata S. *Augmentation of lymphokine-activated killer cell activity by lentinan*. Anticancer Res. 1993;13:1773-1776.
- Wang X.E., Wang Y.H., Zhou Q., Peng M., Zhang J., Chen M.M.L.J., Xie G.M. *Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients*. Pathol. Oncol. Res. 2018;26:499-505. doi: 10.1007/s12253-018-0545-y.
- Shin MS, Park HJ, Maeda T, Nishiooka H, Fujii H, Kang I. *The Effects of AHCC®, a Standardized Extract of Cultured Lentinula edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies*. J Immunol Res. 2019 Dec 20;2019:3758576.
- Yin Z, Fujii H, Walshe T. *Effects of active hexose correlated compound on frequency of CD4+ and CD8+ T cells producing interferon-γ and/or tumor necrosis factor-α in healthy adults*. Hum Immunol. 2010 Dec;71(12):1187-90. Epub 2010 Aug 21. PMID: 20732368.
- Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y. *Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial*. Nutr Cancer. 2008;60(5):643-51.
- Belanger, J. (Lexington Natural Health Center, MA USA). *An In-Office Evaluation of Four Dietary Supplements on Natural Killer Cell Activity*. TOWNSEND LETTER for DOCTORS & PATIENTS (2005), p.88-92
- Smith JA, Mathew L, Gaikwad A, Rech B, Burney MN, Faro JP, Lucci JA, Bai Y, Olsen RJ, Byrd TT. *From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections*. Front Oncol. 2019 Mar 20;9:173.
- Smith JA, Gaikwad AA, Mathew L, Rech B, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT. *AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections*. Front Oncol. 2022 Jun 22;12:881902.
- Salerno J, Sato A. *Effects of AHCC supplementation on Lyme Disease patients*. The Salerno Center for Complementary Medicin, New York; Amino Up Chemical Co, Ltd., Sapporo, Japan.
- Chutaputti A. et al. Presented at 18th ICIM. 2008
- Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y. *Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study*. J Hepatol. 2002 Jul;37(1):78-86.
- Kawaguchi Y. *Improved survival of patients with gastric cancer or colon cancer when treated with active hexose correlated compound (AHCC): effect of AHCC on digestive system cancer*. Nat Med J. 2009;1(1):1-6.

Pagina 32 | Vasten, autofagie en kanker (Edward Blommaart)

- Klionsky DJ, Petroni G, Amaravadi RK, et al. *Autophagy in major human diseases*. EMBO J. 2021;40(19):e108863.
- Santana-Codina N, Mancias JD, Kimmelman AC. *The Role of Autophagy in Cancer*. Annu Rev Cancer Biol. 2017;1:19-39.
- Rajendran P, Alzahrani AM, Hanieh HN, Kumar SA, Ben Ammar R, Rengarajan T, Alhoot MA. *Autophagy and senescence: A new insight in selected human diseases*. Journal of cellular physiology. 2010 234(12):21485-21492
- Zhang Y, Guo R, Wang SS, et al. *Autophagy-related Proteins in Genome Stability: Autophagy-Dependent and Independent Actions*. Int J Biol Sci. 2022;18(14):5329-5344.
- Grivennikov SI, Greten FR, Karin M. *Immunity, inflammation, and cancer*. Cell. 2010;140(6):883-899.
- Mowers EE, Sharifi MN, Macleod KF. *Autophagy in cancer metastasis*. Oncogene. 2017;36(12):1619-1630.
- Rosenfeld MR, Ye X, Supko JG, et al. *A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme*. Autophagy. 2014;10(8):1359-1368.
- Raffaghello L, Lee C, Saffdie FM, et al. *Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy*. Proc Natl Acad Sci U S A. 2008;105(24):8215-8220.
- Eriau E, Paillet J, Kroemer G, Pol JG. *Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy*. Cancers (Basel). 2021;13(6):1260.
- de Gruil N, Pijl H, van der Burg SH, Kroep JR. *Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity*. Cancers (Basel). 2022;14(6):1390.
- Brandhorst S, Longo VD. *Fasting and Caloric Restriction in Cancer Prevention and Treatment*. Recent Results Cancer Res. 2016;207:241-266.
- Patra S, Pradhan B, Nayak R, et al. *Apoptosis and autophagy modulating dietary phytochemicals in cancer therapeutics: Current evidences and future perspectives*. Phytother Res. 2021;35(8):4194-4214.
- Clifton KK, Ma CX, Fontana L, Peterson LL. *Intermittent fasting in the prevention and treatment of cancer*. CA Cancer J Clin. 2021;71(6):527-546.

Pagina 38 | Darmmicrobioom voert de lever alcohol (Vera van Randwijck)

- Meijnikman A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., Kemper, M., Holleboom, A. G., Tushuizen, M. E., Schwartz, T. W., Nielsen, J., Brandjes, D., Dirinck, E., Weyler, J., Verrijken, A., ... Nieuwdorp, M. (2022). *Microbiome-derived ethanol in nonalcoholic fatty liver disease*. Nature Medicine, 28(10), 2100-2106.
- Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018). *Alcoholic liver disease*. In Nature Reviews Disease Primers (Vol. 4, Issue 1). Nature Publishing Group.
- Arab, J. P., Arrese, M., & Trauner, M. (2018). *Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease*. Annu. Rev. Pathol. Mech. Dis, 13, 321-350.
- Toshikuni, N., Tsutsumi, M., & Arisawa, T. (2014). *Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease*. In World Journal of Gastroenterology (Issue 26, pp. 8393-8406). WJG Press.
- Maag Lever Darmstichting (2017). *Niet-alcoholische leververvetting (NAFLD/NASH)*. Geraadpleegd op 3 december 2022 via <https://www.mlds.nl/chronische-ziekten/niet-alcoholische-leververvetting-naflid-nash/>
- Kennisinstituut bier (geen datum). *Metabolisme*. Geraadpleegd op 3 december 2023 via <https://www.kennisinstituutbier.nl/gezondheid/gezondheid/metabolisme>

Pagina 44 | IBD, leefstijlgeneeskunde en de MDL-arts (Cindy de Waard)

- Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. *STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD*. Gastroenterology. 2021 Apr 1;160(5):1570-83.
- Roberts-Thomson IC, Bryant R V., Costello SP. *Uncovering the cause of ulcerative colitis*. JGH Open. 2019 Aug 1;3(4):274-6.
- Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. *Environmental Risk Factors for Inflammatory Bowel Diseases: A Umbrella Review of Meta-analyses*. Gastroenterology. 2019 Sep 1;157(3):647-659.e4.
- Van Der Sloot KWJ, Weersma RK, Alizadeh BZ, Dijkstra G. *Identification of Environmental Risk Factors Associated with the Development of Inflammatory Bowel Disease*. J Crohn's Colitis. 2020 Dec 2;14(12):1662-71.
- Wintjens DSJ, De Jong MJ, Van Der Meulen-De Jong AE, Romberg-Camps MJ, Bex MC, Maljaars JP, et al. *Novel Perceived Stress and Life Events Precede Flares of Inflammatory Bowel Disease: A Prospective 12-Month Follow-Up Study*. Vol. 13, Journal of Crohn's and Colitis. Oxford Academic; 2019. p. 410-6.
- van der Sloot KWJ, Tiems JL, Visschedijk MC, Festen EAM, van Dullemen HM, Weersma RK, et al. *Cigarette Smoke Increases Risk for Colorectal Neoplasia in Inflammatory Bowel Disease*. Clin Gastroenterol Hepatol. 2022 Apr 1;20(4):798-805.e1.
- Campmans-Kuijpers MJE, Dijkstra G. *Food and food groups in inflammatory bowel disease (Ibd): The design of the Groningen anti-inflammatory diet (graid)*. Nutrients. 2021 Mar 25;13(4):1067.
- MindIBD - Radboudumc. <https://www.radboudumc.nl/lopende-onderzoeken/mindibd>
- IBD Fit® | IBD-centrum. <https://www.asz.nl/specialismen/mdl/ibd-centrum---mdl-ibd-fit-/>
- Met het ENERGIZE IBD project minder vermoeidheid bij IBD - Maag Lever Darm Stichting. <https://www.mlds.nl/chronische-ziekten/wetenschappelijk-onderzoek/met-het-energize-ibd-project-minder-vermoeidheid-bij-ibd>

Pagina 50 | Paradigma's overgewicht (Fleur Kortekaas)

- Ludwig, D.S., Apovian, C.M., Aronne, L.J. et al. *Competing paradigms of obesity pathogenesis: energy balance versus carbohydrate-insulin models*. Eur J Clin Nutr 76, 1209-1221 (2022).

Pagina 57 | Virale arteriosclerose (Angélique De Beule)

- WHO – *Cardiovascular diseases (CVDs)*- fact sheet 2021.
- Shi, Zhang et al. *COVID-19 and atherosclerosis: looking beyond the acute crisis*. Emergency and Critical Care Medicine. March 2022 - Volume 2 - Issue 1 - p 1-4.
- Nick S, Nurmohamed et al. *Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study*. Atherosclerosis. VOLUME 341, P43-49, JANUARY 01, 2022.
- Agnieszka Pawlos et al. *Elevated Lp(a) and course of COVID-19: Is there a relationship?* PLOS ONE 2022 17(6).
- Adem Keskin et al. *Homocysteine as a marker for predicting disease severity in patients with COVID-19*. Biomarkers in medicine 2022 Vol. 16, No. 7.
- Pushkarev et al. *Plasma Apolipoproteins A1/B and OxLDL Levels in Patients with Covid-19 As Possible Markers of the Disease*. Cytology and Genetics volume 55, pages519-523 (2021).
- Micholas Dean Smith and Jeremy C. Smith. *Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface*. Chemrxiv 2020.
- Husam Dabbagh-Bazarbachi et al. *Zinc Ionophore Activity of Quercetin and Epigallocatechin-gallate: From Hepa 1-6 Cells to a Liposome Model*. July 2014 Journal of Agricultural and Food Chemistry 62(32).
- Majambu Mbikay et al. *Isoquercetin as an Anti-Covid-19 Medication: A Potential to Realize*. Front. Pharmacol. 02 March 2022 Sec. Pharmacology of Infectious Diseases.
- James J. DiNicolantonio et al. *Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in covid-19 patients*. Mo Med. 2021 Jan-Feb; 118(1): 68-73.
- Goddek S et al. *Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate*. August 2020. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases.
- Fanni D et al. *Trace elements and the carotid plaque: the GOOD (Mg, Zn, Se), the UGLY (Fe, Cu), and the BAD (P, Ca)?* European Review for Medical and Pharmacological Sciences 2021; 25: 3772-3790.
- Avery, Joseph C, and Peter R Hoffmann. *Selenium, Selenoproteins, and Immunity*. Nutrients vol. 10,9 1203. 1 Sep. 2018.
- Mahmoodpoor A et al. *The Effect of Intravenous Selenium on Oxidative Stress in Critically Ill Patients with Acute Respiratory Distress Syndrome*. Immunol Invest. 2019 Feb;48(2):147-159.